This is the authors' abstract. We don't add key points for this paper.
: Despite promising advances, challenges remain due to the rarity and phenotypic heterogeneity of SGCs, emphasizing the need for molecularly stratified clinical trials. This review presents an overview of tissue and liquid biomarkers, focusing on molecular targets and therapeutic innovations that lay the foundation for improved diagnostic and treatment strategies for SGCs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Broseghini et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: